EHA 2018 | Novel agents in AML: highlights from EHA 2018
The development of novel agents to treat acute myeloid leukemia (AML) is constantly revolutionizing the field. In this video, Christoph Röllig, MD, of the University Hospital Carl Gustav Carus, Dresden, Germany, speaks about his highlights from the novel agent discussions held at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. These vary from new immunotherapeutic treatments to FLT3 inhibitors, to small molecules like venetoclax and glasdegib, all of which have yielded positive results in clinical trials.
Get great new content delivered to your inboxSign up